Available EXPANDED_ACCESS NCT07158827
Expanded Access to Tavapadon
Sponsor: AbbVie
Conditions
Parkinson Disease
Interventions
Tavapadon
Updated 3 times since 2025 Last updated: Feb 6, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07158827, this observational or N/A phase trial focuses on Parkinson Disease and remains ongoing. Sponsored by AbbVie, it has been updated 3 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
3 versions recorded-
Feb 2026 — Present [monthly]
Available
-
Dec 2025 — Feb 2026 [monthly]
Available
-
Oct 2025 — Dec 2025 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- AbbVie
Data source: AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.